Johns Hopkins Study Confirms Long-Term Benefits of Psilocybin for Depression

Researchers find significant and lasting reductions in depression symptoms after just two guided psilocybin sessions.

Landmark Long-Term Results

Johns Hopkins University has published the results of the longest follow-up study to date on psilocybin-assisted therapy for major depressive disorder, and the findings are remarkable. The study, published this week in JAMA Psychiatry, followed 104 participants for 24 months after they received two psilocybin sessions as part of a structured therapeutic protocol.

The results show that the benefits of psilocybin therapy are not just rapid—they're remarkably durable. At the 24-month mark, 75% of participants still showed clinically significant improvement in their depression symptoms, and 58% met criteria for full remission. These numbers far exceed what's typically seen with traditional antidepressant medications over similar timeframes.

Study Design and Methods

The study built on Johns Hopkins' previous groundbreaking work with psilocybin. Participants were adults with moderate to severe major depressive disorder who had not responded adequately to at least two previous antidepressant treatments.

Protocol: • Two psilocybin sessions (25mg) spaced two weeks apart • Each session lasted approximately 6 hours with trained facilitators • Extensive preparation before and integration therapy after each session • No additional psilocybin sessions during the follow-up period

Assessments: • GRID-Hamilton Depression Rating Scale (primary outcome) • Beck Depression Inventory • Quality of life measures • Assessments at 1, 3, 6, 12, 18, and 24 months

Importantly, participants were not given any additional psilocybin during the follow-up period, meaning the sustained benefits came from just two sessions.

Key Findings

The study's findings were striking across multiple measures:

Depression Severity: • Average depression scores dropped by 71% at one month • At 24 months, average scores remained 54% below baseline • 75% of participants showed clinically significant response • 58% achieved and maintained full remission

Quality of Life: • Significant improvements in overall life satisfaction • Better social functioning and relationships • Increased sense of meaning and purpose • Reduced anxiety symptoms

Comparison to Antidepressants: • Traditional antidepressants show ~30-40% remission rates • Relapse rates with antidepressants are typically 50%+ within two years • Psilocybin's 58% sustained remission rate significantly exceeds this benchmark

What Makes Psilocybin Different

Lead researcher Dr. Roland Griffiths, who has pioneered psilocybin research at Johns Hopkins for two decades, offered insights into why psilocybin may produce such lasting effects:

"Traditional antidepressants work by modulating neurotransmitter levels, which requires continuous dosing and often loses efficacy over time. Psilocybin appears to work through a fundamentally different mechanism—it seems to create a window of increased neuroplasticity during which therapeutic insights can lead to lasting changes in perspective and behavior."

The study found that participants who reported more profound mystical-type experiences during their psilocybin sessions tended to have better long-term outcomes, suggesting that the subjective quality of the experience matters, not just the pharmacological effects.

"Many participants described their psilocybin sessions as among the most meaningful experiences of their lives," noted co-author Dr. Matthew Johnson. "That kind of profound experience, properly integrated, can shift how someone relates to themselves and their depression in ways that persist."

Implications for Treatment

The study's authors believe these findings have significant implications for how we approach depression treatment:

A New Treatment Paradigm: • Rather than daily medication, psilocybin offers a model of intensive, infrequent treatment • Two sessions producing two years of benefit represents a dramatic shift in treatment economics • Could reduce the burden of daily medication and associated side effects

Who Might Benefit: • Particularly promising for treatment-resistant depression • May be especially valuable for those who haven't responded to multiple medications • The study specifically enrolled patients who had failed previous treatments

Remaining Questions: • Would periodic "booster" sessions extend benefits even further? • Can the protocol be adapted for different populations? • How do results compare in real-world clinical settings vs. research environments?

The Road to Approval

This study adds to the growing body of evidence supporting psilocybin's therapeutic potential. The FDA has already granted Breakthrough Therapy designation to psilocybin for treatment-resistant depression, and several Phase 3 clinical trials are underway.

"We're cautiously optimistic that psilocybin could receive FDA approval for depression within the next few years," said Dr. Griffiths. "Studies like this one are crucial for demonstrating not just that psilocybin works, but that it works durably—which is essential for regulatory approval and for making the case that this should be a standard treatment option."

For the millions of Americans living with treatment-resistant depression, these findings offer genuine hope. While psilocybin therapy is not yet widely available, Oregon's legal program and ongoing clinical trials are making access increasingly possible for those who might benefit.

Key Takeaways

A new Johns Hopkins study following participants for 24 months found that 75% of those who received psilocybin-assisted therapy maintained clinically significant improvements in depression, with 58% still in remission—far exceeding the long-term efficacy of traditional antidepressants.